All In Biotech

Drug Trial Radar · NCT07758985

Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

A Phase 1b, Single-Center, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Mosquitocidal Activity of Single Oral Doses of Lotilaner in Healthy Participants in Mali.

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Medicines for Malaria VentureAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Radboud University Medical Center; London School of Hygiene and Tropical Medicine; Malaria Research and Training Center, Bamako, Mali
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy, adult participants living in Mali.

Conditions

  • Malaria

Interventions

  • Cohort 1 low dose lotilaner with a high-fat mealDrug

    Participants will receive a single low dose of lotilaner with a high-fat meal

  • Cohort 1 low dose placebo with a high-fat mealOther

    Participants will receive a single low dose of placebo with a high-fat meal

  • Cohort 2 high dose lotilaner in fasted stateDrug

    Participants will receive high dose lotilaner in a fasted state

  • Cohort 2 high dose placebo in fasted stateOther

    Participants will receive a single high dose of placebo in a fasted state

  • Cohort 3 high dose lotilaner with a high-fat mealDrug

    Participants will receive a single high dose of lotilaner after a high-fat meal

  • Cohort 3 high dose placebo with a high-fat mealOther

    Participants with receive a single high dose of placebo with a high-fat meal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of LotilanerTime frame: From hour 0 on Day 1 through the end of the study (Day 169)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Malaria Research and Training Center

    Bamako, Mali · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.